Related Experiment Video
Updated: Jun 22, 2026
08:15
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Improving antidepressant drugs: update on recently patented compounds
1University of Dublin, School of Chemistry, Trinity College, Dublin 2, Ireland. rozasi@tcd.ie
Expert Opinion on Therapeutic Patents
|May 29, 2009
Summary
Recent patent analysis reveals that while serotonin and noradrenaline remain key targets for new antidepressants, multi-target drugs are preferred for better efficacy. Emerging research also explores novel systems like the melatonergic pathway.
Area of Science:
- Pharmacology and Drug Discovery
- Neuroscience
- Intellectual Property in Medicine
Background:
- Depression affects approximately 121 million people globally.
- The exact cause of depression remains unknown.
- Current antidepressants primarily increase brain monoamine levels (serotonin, noradrenaline).
Purpose of the Study:
- To identify potential antidepressant drugs and their targets from recent patents.
- To analyze pharmaceutical companies' development of antidepressant compounds.
- To assess market size and prospects for new antidepressants.
Main Methods:
- Searched the European Patent Office (esp@cenet) database for "antidepressants" (2005-2008).
- Utilized the Medtrack database for pharmaceutical development information.
- Analyzed patent data and market intelligence.
Main Results:
- Serotonergic and noradrenergic systems are still primary targets for antidepressant development.
- Multi-target drugs are increasingly favored over highly selective ones due to efficacy concerns.
- Novel targets like the melatonergic system are emerging.
- A trend towards dual-action drugs for depression and schizophrenia is observed.
Conclusions:
- Antidepressant drug development continues to focus on monoamine systems but with a shift towards multi-target approaches.
- Emerging drug candidates show potential for broader applications, including comorbid conditions.
- Patent and market analysis indicates evolving strategies in antidepressant research and development.
Related Concept Videos
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...